Filing Flows

Filing Flows › Health Care › Capricor Therapeutics (CAPR)

Capricor Therapeutics (CAPR) earnings and revenue breakdown

Latest: Q4 2024 · 10-K filed Mar 26, 2025 · Capricor Therapeutics (CAPR) Q4 2024 earnings results →

Q4 2024 Revenue down 8% year over year to $11.1M · 64¢ of every $1 of revenue lost · operating margin -69.1%

Capricor Therapeutics made $11.1M in Q4 2024 (-8% Y/Y). Operating margin -69.1%, net loss $7.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-K filed Mar 26, 2025.

Revenue$11.1M
Year over year-8%
Operating margin-69.1%
Net earnings−$7.1M
Operating cash flow−$14.8M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $11.1M in Q4 2024, down 8% year over year and up 392% from the previous quarter.

Operating costs exceeded revenue by $7.7M, an operating margin of -69.1%. Total costs grew 41% against a revenue fall of 8%. The fastest-growing cost line was Research & development (+46%). The quarter ended with a net loss of $7.1M, narrower than the previous quarter's $12.6M loss.

Operating cash flow was −$14.8M. Non-cash charges added back $376K of depreciation and $2.3M of share-based compensation. Working capital and other items used $10.4M. Capital expenditures of $489K exceeded it, leaving free cash flow of −$15.3M.

Quarterly history

QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q4 202410-KMar 26, 2025$11.1M-8%-69.1%−$7.1M−$14.8M

Charts

Capricor Therapeutics: where the cash came from (+) and went (−), TTM to Q2 2026Capricor Therapeutics: where the cash came from (+) and went (−), TTM to Q2 2026Other financing$231MOther investing−$133MOperating cash flow−$104MShares issued$15.4MCapital spending−$10.9MCash drawn (+) / kept (−)$2.3M
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Capricor Therapeutics: profit against cash, quarter by quarterCapricor Therapeutics: profit against cash, quarter by quarterNet incomeOperating cash flow−$12.6M−$11.6MQ3 2024−$7.1M−$14.8MQ4 2024−$24.4M−$6.4MQ1 2025−$25.9M−$20.1MQ2 2025−$24.6M−$19.7MQ3 2025−$30.2M−$23.6MQ4 2025−$33.9M−$29.3MQ1 2026−$40.7M−$31.5MQ2 2026
Latest (Q2 2026): Net income −$40.7M, Operating cash flow −$31.5M.
Capricor Therapeutics: diluted shares by fiscal yearCapricor Therapeutics: diluted shares by fiscal year16MFY202023MFY202125MFY202227MFY202335MFY202446MFY2025
+198.5% since FY2020: more shares outstanding (issuance, stock pay).
Capricor Therapeutics in its industry: growth against margin (225 companies, SIC 2834)Capricor Therapeutics in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMCAPR (-8%, -69%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Capricor Therapeutics

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. Since our inception, we have devoted substantial resources to developing deramiocel and our other product candidates including our exosomes platform technology, developing our manufacturing processes, staffing our company and providing general and administrative support for these operations. We do not have any products approved for commercial sale.

In its own words, from its 10-K, filed Mar 26, 2025.

Capricor Therapeutics against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -8% against the peers' median +7%. Operating margin: -69.1% against the peers' median 20.4%.

CompanyQuarterRevenueY/YOp. margin
CAPR Capricor TherapeuticsQ4 2024$11.1M-8%-69.1%
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Capricor Therapeutics 10-K on SEC EDGAR · CIK 1133869 · Pharmaceutical Preparations

13F: who owns CAPR and who is buying

Largest holders of CAPR (13F)Largest holders of CAPR (13F)BlackRock$99.8MTang Capital Management LLC$98.7MSuvretta Capital Management, LLC$98.6MState Street$81.8MVanguard Group$73.9MVanguard Capital Management LLC$55.3MGoldman Sachs Group$38.0MRA Capital Management, L.P.$36.3MBoxer Capital Management, LLC$33.6MGeode Capital Management, LLC$33.0M
Funds' net buying of CAPR by quarter (13F)Funds' net buying of CAPR by quarter (13F)$18.8M2024-09$6.7M2024-12$10.4M2025-03−$26.3M2025-06$3.8M2025-09$366M2025-12$177M2026-03$130M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on CAPR

History

Every quarter: Q4 2024 results

Compare CAPR with

中文版：Capricor Therapeutics（CAPR）财报

Español · Français